17th week of 2016 patent applcation highlights part 9 |
Patent application number | Title | Published |
20160113991 | Aqueous Solution Formulated to Raise Body Temperature - An aqueous solution that is useful for helping to increase body temperature in people with chronic low body temperature, as well as people who suffer from cold hands and feet, includes a combination of ginseng, cinnamon, ginger, and jasmine tea. The body temperature raising solution may be in the form of a beverage and include a sweetener, such as honey, to improve the taste thereof. The body temperature raising solution is formulated by steeping leaves of the jasmine tea in a host liquid, suspending predetermined amounts of the ginseng, cinnamon, ginger, and honey into the host liquid, and storing the combination in an airtight container. | 2016-04-28 |
20160113992 | COMBINATIONS OF EXTRACTS OF SERENOA REPENS AND LIPOPHILIC EXTRACTS OF ZINGIBER OFFICINALIS AND ECHINACEA ANGUSTIFOLIA, THE USE THEREOF, AND FORMULATIONS CONTAINING THEM - Disclosed are compositions containing an extract of | 2016-04-28 |
20160113993 | THERAPEUTIC VITAMIN D CONJUGATES - The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone. | 2016-04-28 |
20160113994 | METHOD OF TREATING PATIENTS WITH HEPATORENAL SYNDROME TYPE 1 - The principles and embodiments of the present disclosure relate to methods for using terlipressin to treat a patient having impaired renal function associated with liver disease. A patient identified as suffering from HRS-1 is tested to determine if the patient meets at least two out of three criteria, wherein the three criteria include a WBC<4 or >12 cells/4; HR>90 bpm; and any one of HCO | 2016-04-28 |
20160113995 | LIPID NANOPARTICLE OF POLYMYXIN - A lipid nanoparticle that includes at least one antibiotic from the polymyxin family, a lipid fraction, and one or more surfactants. The lipid nanoparticle is useful in the prevention and/or treatment of respiratory tree infections. | 2016-04-28 |
20160113996 | TAFA4 COMPOUNDS AND USES THEREOF FOR TREATING PAIN - The present invention relates to novel compounds for use for preventing, alleviating or treating pain in a subject. Also herein described are pharmaceutical compositions, their preparation and uses as well as methods for preventing, alleviating or treating pain using such compounds and compositions. | 2016-04-28 |
20160113997 | BETA-CASEIN A2 AND PREVENTION OF INFLAMMATION OF THE BOWEL - The use of a composition for preventing or reducing the risk of inflammation of the bowel in an animal, wherein the composition contains beta-casein and wherein the beta-casein comprises at least 50% by weight beta-casein A2. | 2016-04-28 |
20160113998 | Methods for Treating Congestive Heart Failure - The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene. | 2016-04-28 |
20160113999 | Therapeutic Dosing of a Neuregulin or a Subsequence Thereof for Treatment or Prophylaxis of Heart Failure - The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects. | 2016-04-28 |
20160114000 | CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS - Described are peptide analogs of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have relatively balanced agonist activity at the glucagon-like peptide 1 (GLP-1) receptor and the glucagon (GCG) receptor, and the use of such GLP-1 receptor/GCG receptor co-agonists for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity. | 2016-04-28 |
20160114001 | INSULIN VITAMIN D CONJUGATES - The invention provides non-hormonal vitamin D conjugated to insulin peptides that result in the peptides having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the insulin peptides via the third carbon on the vitamin D backbone. | 2016-04-28 |
20160114002 | COMPOSITIONS COMPRISING PLANT PROTEINS AND METHODS FOR PREVENTION OF METABOLIC AND CARDIOVASCULAR PATHOLOGIES IN PATIENT WITH CARDIOMETABOLIC RISK, INCLUDING HYPERGLYCEMIA - A composition for oral administration in humans comprising at least one plant protein chosen from pea proteins, rice proteins or a mixture thereof, and:
| 2016-04-28 |
20160114003 | PHARMACEUTICAL COMPOSITIONS COMPRISING COLLAGEN AND SODIUM HYALURONATE - The present invention relates to pharmaceutical compositions comprising collagen and hyaluronic acid, and optionally containing silver. | 2016-04-28 |
20160114004 | ROLE OF A CLUSTER OF LONG NONCODING RNA TRANSCRIPTS IN PROTECTING THE HEART FROM PATHOLOGICAL HYPERTROPHY - Nucleic acids encoding modified myosin heavy-chain-associated RNA transcripts are provided. The modified myosin heavy-chain-associated RNA transcripts belongs to a cluster of long noncoding RNAs (lncRNA) and bind to chromatin remodeler Brg1 to inhibit Brg1's genomic targeting and gene regulation function. The modified myosin heavy-chain-associated RNA transcripts expressed in an individual inhibit Brg1's gene regulation function and protect the heart of the individual from myopathy and failure. One of the modified heavy-chain-associated RNAs is a 400 base pair fragment segmented from a natural 779 base pair sequence of Mhrt (Mhrt779) and has the same cardioprotective effects as the Mhrt779. | 2016-04-28 |
20160114005 | HYBRID PROTEIN THAT CONVERTS ARACHIDONIC ACID INTO PROSTACYCLIN - A recombinant 130-kDa protein is constructed by linking together human cyclooxygenase (COX) isoform-2 (COX-2) and prostacyclin synthase (PGIS), via a 10-20 amino acid residues of a transmembrane sequence. The engineered protein is expressed in cells, and adopts the functions of COX and PGIS, to continually convert arachidonic acid (AA) into prostaglandin G | 2016-04-28 |
20160114006 | COMPOSITIONS AND METHODS FOR TREATMENT OF RETINAL DEGENERATIVE DISEASES - This disclosure relates to compositions for use in treatment of a retinal degenerative disease, such as age related macular degeneration. The described compositions include agents for activating p38 and/or JNK signaling through the activation of TAK1 in the retinal pigment epithelium of a subject diagnosed with the disease. Methods of treatment of a retinal degenerative disease using the described compositions are also provided. | 2016-04-28 |
20160114007 | COMPOSITION FOR PREVENTING OR TREATING AUTOIMMUNE DISEASE, COMPRISING, AS ACTIVE INGREDIENT, PINK1 PROTEIN OR POLYNUCLEOTIDE ENCODING SAME - The present invention relates to a composition for preventing or treating an autoimmune disease comprising, as an active ingredient, PINK1 protein or polynucleotide encoding the same. The PINK1 protein according to the present invention inhibits the activity of Th17, promotes the activity of a regulatory T cell (Treg), and increases autophagy in Treg cells, thereby controlling excessive immune responses. Therefore, the PINK1 protein can be effectively used as a pharmaceutical composition or an immunosuppressant, which is capable of preventing or treating an autoimmune disease, such as arthritis, and the like, caused by dysregulation of various kinds of immune responses. | 2016-04-28 |
20160114008 | Methods for accelerating the healing of connective tissue injuries and disorders - The invention is directed to methods for accelerating the healing of connective tissue injuries and disorders. In particular, the invention is directed to accelerating the healing of injuries and disorders of tendons and ligaments. Such methods utilize novel compositions including, but not limited to, extraembryonic cytokine-secreting cells (herein referred to as ECS cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), including pooled ACCS, and Physiologic Cytokine Solution (PCS). | 2016-04-28 |
20160114009 | Proteases Able to Hydrolyze Gluten Peptides and Proteins at Acidic PH, from the Actinomycete Actinoallomurus - The invention relates to a new family of proteolytic enxymes having the ability to hydrolize at a pH between 3 and 8 gluten olygopeptides which are resistant to cleavage by gastric and pancreatic enzymes and whose presence in the intestinal lumen results in toxic effects. The enzymes have been identified as endopeptidases of the S8/S53 family and are produced by an | 2016-04-28 |
20160114010 | METHODS FOR TREATING BLEEDING DISORDERS USING A PLATELET SUBPOPULATION - The present invention relates to a platelet subpopulation with high binding capacity to recombinant activated factor VII (rFVIIa), and its use for the treatment of bleeding disorders and for determining whether a subject is a candidate for treatment with rFVIIa. | 2016-04-28 |
20160114011 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS - The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules. | 2016-04-28 |
20160114012 | ENZYME FORMULATION FOR USE AS FOOD SUPPLEMENT - The present document describes an enzyme formulation comprising an enzyme mixture comprising from about 5% to about 45% (wt/wt) of a fungal protease enzyme; and from about 1.5% to about 50% (wt/wt) of at least one polysaccharide digesting enzyme; in combination with an acceptable pharmaceutical carrier. The present document also describes the use of the formulation of the present invention for the prevention or treatment of digestive disorder. | 2016-04-28 |
20160114013 | PHARMACEUTICAL COMPOSITION COMPRISING A BOTULINUM NEUROTOXIN AND USES THEREOF - The invention relates a pharmaceutical composition containing botulinum toxin and a mucopolysaccharide uses thereof with increased pharmacological activity and long lasting botulinum toxin effect. | 2016-04-28 |
20160114014 | Compositions and Methods for Topical Application and Transdermal Delivery of Botulinum Toxins - A composition for topical application of a | 2016-04-28 |
20160114015 | TREATMENT OF SOCIAL ANXIETY DISORDER, OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER USING BOTULINUM TOXIN - Methods are disclosed for treating social anxiety disorder, obsessive compulsive disorder, and/or panic disorder in a subject. The methods include administering a therapeutically effective amount of a neurotoxin to a corrugator supercilli and/or a procerus muscle of the subject to cause paralysis of the corrugator supercilli and/or a procerus muscle in the subject, thereby treating PTSD. The neurotoxin can be Botulinum toxin A, such as at a dose of about 20 to about 50 units of Botulinum toxin A. | 2016-04-28 |
20160114016 | COMPOSITIONS AND METHODS COMPRISING GLYCYL-TRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES - Isolated glycyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto. | 2016-04-28 |
20160114017 | INTERLEUKIN-13 RECEPTOR ALPHA 2 PEPTIDE-BASED BRAIN CANCER VACCINES - Provided herein are interleukin-13 receptor α2 peptide-based brain cancer vaccines and methods for treating and vaccinating against brain cancer comprising administering to patients in need thereof interleukin-13 receptor α2 peptide-based brain cancer vaccines. Also provided herein are regimens comprising interleukin-13 receptor α2 peptides and at least one additional peptide and/or immunostimulant. | 2016-04-28 |
20160114018 | IMP-3 EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING THE SAME - Isolated IMP-3-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce IMP-3-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors including, for example, bladder cancer, cervical cancer, cholangiocellular carcinoma, chronic myelocytic leukemia, colon cancer, rectum cancer, esophageal cancer, gastric diffuse-type cancer, non-small-cell lung cancer (NSCLC), small-cell lung cancer (SCLC), lymphoma, osteosarcoma, ovarian cancer, renal carcinoma, soft tissue tumor, testicular tumor, and HNC. | 2016-04-28 |
20160114019 | WT1 ANTIGEN PEPTIDE CONJUGATE VACCINE - A compound represented by the formula (1): | 2016-04-28 |
20160114020 | Targets and compositions for use in decontamination, immunoprophylaxis, and post-exposure therapy against anthrax - The present invention relates to the decontamination of anthrax spores, prophylaxis and treatment of anthrax infections and, more particularly, to compounds that act as specific inhibitors of | 2016-04-28 |
20160114021 | NOVEL SURFACE EXPOSED HAEMOPHILUS INFLUENZA PROTEIN (PROTEIN E; pE) - The present invention relates to a surface exposed protein (protein E; pE), a virulence factor, which can be detected in | 2016-04-28 |
20160114022 | THERAPIES, VACCINES, AND PREDICTIVE METHODS FOR FILOVIRUSES INCLUDING EBOLAVIRUS AND MARBURG VIRUS - The present invention provides therapies, vaccines, and predictive methods for Filoviruses, including Ebolaviruses and Marburg viruses, and provides compounds for diagnosing, preventing, and treating outbreaks of Filoviruses. | 2016-04-28 |
20160114023 | CANCER AND SKIN LESION TREATMENT - A method for treating or reducing the incidence of recurrence of cancer, benign tumors or HPV-associated lesions, including skin cancer, and particularly squamous cell carcinoma (SCC and basal-cell carcinoma, by administering one or more doses of HPV recombinant vaccine to a patient. | 2016-04-28 |
20160114024 | LACTIC ACID BACTERIUM, DRUG, FOOD OR DRINK, AND FEED WHICH CONTAIN THE LACTIC ACID BACTERIUM | 2016-04-28 |
20160114025 | COMPOSITIONS AND METHODS OF ENHANCING IMMUNE RESPONSES - Provided herein are | 2016-04-28 |
20160114026 | PAN-LYSSAVIRUS VACCINES AGAINST RABIES - Described herein are recombinant rabies viruses encoding rabies virus glycoprotein and at least one heterologous glycoprotein from another lyssavirus, such as Mokola virus, Lagos bat virus and/or West Caucasian bat virus. In particular embodiments, the recombinant rabies virus includes two or three heterologous lyssavirus glycoproteins. The disclosed recombinant rabies viruses can be used as pan-lyssavirus vaccines to provide protection against lyssaviruses that cause rabies. | 2016-04-28 |
20160114027 | RECOMBINANT HCMV AND RHCMV VECTORS AND USES THEREOF - The present disclosure relates to recombinant rhesus cytomegalovirus (RhCMV) and human cytomegalovirus (HCMV) vectors encoding heterologous antigens, such as pathogen-specific antigens or tumor antigens, which may be used, for example, for the treatment or prevention of infectious disease or cancer. The recombinant RhCMV or HCMV vectors elicit and maintain high level cellular immune responses specific for the heterologous antigen while including deletions in one or more genes essential or augmenting for CMV replication, dissemination or spread. | 2016-04-28 |
20160114028 | DNA MOTIF COMPOUNDS AND METHODS FOR INDUCING SPECIFIC ANTIBODIES AND CELLULAR IMMUNITY - The present invention relates to the field of applied immunotechnology and medicine. More specifically, it relates to DNA motif vaccine design, glyco-DNA motif vaccine design, and immunogen design for producing antibodies against an epitope of arbitrary sequences or polysaccharide epitope, particularly those epitopes against which it is otherwise very difficult to induce antibodies, such as those of HIV-1. The present invention also relates to immunogen design to induce robust cellular and humoral immunity. | 2016-04-28 |
20160114029 | PORCINE PSEUDORABIES VIRUS, VACCINE COMPOSITION AND PREPARATION METHOD AND USE THEREOF - Provided in the embodiments of the present invention is a vaccine composition including an immune amount of attenuated live vaccine, inactivated vaccine, subunit vaccine, synthetic vaccine, or genetically engineered vaccine of the porcine pseudorabies virus strain. The vaccine composition can effectively induce antibody generation, and prevent infections of virulent strains of the porcine pseudorabies virus, and provides effective protection for pigs. | 2016-04-28 |
20160114030 | Nucleic Acid Molecule Encoding Hepatitis B Virus Core Protein And Surface Antigen Protein And Vaccine Comprising The Same - Provided herein are nucleic acid sequences encoding hepatitis B virus (HBV) core proteins, surface antigen proteins, fragments and combinations thereof as well as genetic constructs/vectors and vaccines that express said protein sequences. These vaccines are able to induce an immune response peripherally and in the liver by recruiting both cellular and humoral agents. Also provided are methods for prophylactically and/or therapeutically immunizing individuals against HBV. The combination vaccine can also be used for particular design vaccines for particular levels of immune responses to HBV challenge. | 2016-04-28 |
20160114031 | RECOMBINANTLY PRODUCED ALLERGENS - Methods for producing an allergen composition, methods for in vitro diagnosis of type I allergy, and diagnostic kits for performing diagnosis employ Bos d 23k allergen of SEQ ID NO: 4, or the mature protein thereof, or a variant or fragment of the Bos d 23k allergen or the mature protein sharing epitopes for antibodies with the Bos d 23k allergen or the mature protein. Methods for treatment of a Type I allergy to a mammal and pharmaceutical compositions employ a Bos d 23k allergen of SEQ ID NO: 4, or the mature protein thereof, or a variant or fragment of the Bos d 23k allergen or the mature protein sharing epitopes for antibodies with the Bos d 23k allergen or the mature protein, wherein the Bos d 23k allergen, the mature protein, the variant or the fragment is modified to abrogate or attenuate its IgE binding response. | 2016-04-28 |
20160114032 | BACTERIOPHAGE-POLYMER HYBRID - The invention provides a targeted bacteriophage-polymer complex comprising a recombinant targeted-bacteriophage and a cationic polymer. The complex has a net positive charge. The invention provides methods of preparing bacteriophages and complexes thereof, and to their uses for the delivery of transgenes in a variety of gene therapy applications. | 2016-04-28 |
20160114033 | ALUMINUM COMPOUNDS FOR USE IN THERAPEUTICS AND VACCINES - The invention relates to means and methods for preparing aqueous composition comprising aluminium and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminium content. The invention further relates to aqueous compositions comprising a protein and an aluminium-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition. | 2016-04-28 |
20160114034 | COMPOSITIONS COMPRISING ISCOM PARTICLES AND LIVE MICRO-ORGANISMS - Iscom particles can be used as an adjuvant for preparing of an antigenic composition which comprises live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A composition may comprise at least one iscom particle and one or more live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A kit can comprise at least one compartment containing at least one living organism and at least one compartment containing at least one iscom particle. | 2016-04-28 |
20160114035 | PAN-DR Binding Polypeptides and Uses Thereof - The present invention provides novel artificial oligopeptides capable of binding HLA Class II molecules encoded by several alleles. The oligopeptides include the sequence AX | 2016-04-28 |
20160114036 | COMPOSITION FOR STABILIZING PROTEIN AND PHARMACEUTICAL FORMULATION COMPRISING THE SAME - The present invention relates to a composition for stabilizing TNFα-binding protein exhibiting physiological activity, and more specifically, to a composition for stabilizing protein including basic amino acid and sugar and/or ammonium salt, a pharmaceutical formulation including the same, and a method for stabilizing TNFα-binding protein. The formulation including basic amino acid; and sugar and/or ammonium salt according to the present invention effectively inhibits aggregation, denaturation and oxidation of TNFα-binding protein used for treating various diseases, for example, an anti-TNF-alpha antibody, such that the protein is capable of being preserved and stored for a long time, which is widely usable and effective in a medical field using TNFα-binding protein, for example, an anti-TNF-alpha antibody. | 2016-04-28 |
20160114037 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY - The present invention relates to compositions and methods for the treatment of immunodeficiency (e.g., primary immunodeficiency disease). In particular, the invention provides human plasma immunoglobulin compositions containing select antibody titers specific for a plurality of respiratory pathogens, methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions (e.g., for prophylactic administration and/or therapeutic treatment (e.g., passive immunization (e.g., immune-prophylaxis))). | 2016-04-28 |
20160114038 | SCALABLE, MASSIVELY PARALLEL PROCESS FOR MAKING MICRO-SCALE PARTICLES - A method of fabrication produces one or more functional microparticles using a parallel pore working piece. In one embodiment, the method forms a particle that includes a segment for the oxidation of a biofuel (such as glucose) and the reduction of oxygen. The particle may be synthesized in a structure with defined and parallel, uniform, thin pores that completely penetrate the structure. Further, the functional microparticle may be configured to reside in a human or animal body or cell such that it may be self-contained fuel cell having an anode, a cathode, a separator membrane, and a magnetic component. In other embodiments, the functional microparticles may deliver energy or therapeutic materials in the body. | 2016-04-28 |
20160114039 | TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY - Methods for treatment of Polypoidal choroidal vasculopathy (PCV) of the AMD or non-AMD type and pharmaceutical compositions for the use therein are disclosed. | 2016-04-28 |
20160114040 | Derivatized Hyperbranched Polyglycerols - Herein are provided derivatized hyperbranched polyglycerols (“dHPGs”). The dHPG comprises a core comprising a hyperbranched polyglycerol derivatized with C | 2016-04-28 |
20160114041 | TOPICAL COMPOSITIONS AND METHODS FOR MAKING AND USING SAME - The present invention relates to improved topical gel compositions comprising an active agent, and uses thereof. | 2016-04-28 |
20160114042 | AMINE-CONTAINING LIPIDOIDS AND USES THEREOF - Provided herein are lipidoids that may be prepared from the conjugate addition of alkylamines to acrylates. In some embodiments, provided lipidoids are biodegradable and may be used in a variety of drug delivery systems. Given the amino moiety of the lipidoids, they are well-suited for the delivery of polynucleotides, in addition to other agents. Nanoparticles containing the inventive lipidoids and polynucleotides have been prepared and have been shown to be effective in delivering siRNA. | 2016-04-28 |
20160114043 | Stabilized Amine-Containing Actives in Oral Film Compositions - The present invention relates to compositions relating to films containing active pharmaceutical agents. In particular, the present invention relates to methods and systems useful for stabilizing amine-containing actives for dispersion in a film product. | 2016-04-28 |
20160114044 | COMPOSITON BASED ON BIOCOMPATIBLE ANIONIC POLYMER FOR DRUG DELIVERY AND PREPARING METHOD THEREOF - A composition for drug delivery based on a biocompatible anionic polymer and a producing method thereof are provided. | 2016-04-28 |
20160114045 | PHYTOGLYCOGEN NANOPARTICLES AND METHODS OF MANUFACTURE THEREOF - A composition of phytoglycogen nanoparticles purified from a phytoglycogen-containing plant material is provided. The composition of phytoglycogen nanoparticles is monodisperse. A method of isolating the composition from phytoglycogen-containing plant materials is provided that includes steps of microfiltration and ultrafiltration, but avoids the use of chemical, enzymatic or thermo treatments that degrade the phytoglycogen material. | 2016-04-28 |
20160114046 | REFILLABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF - The present invention provides refillable drug delivery systems, as well as methods of refilling the systems, and methods of using them to treat diseases. | 2016-04-28 |
20160114047 | COMPOSITION FOR APPLICATION TO A MUCOSA COMPRISING A METHYLCELLULOSE - A composition designed for application to a mucosa comprises a tonicity-adjusting agent, a methylcellulose, and a liquid diluent, wherein the methylcellulose has anhydroglucose units joined by 1-4 linkages wherein hydroxy groups of anhydroglucose units are substituted with methyl groups such that s23/s26 is 0.36 or less, wherein s23 is the molar fraction of anhydroglucose units wherein only the two hydroxy groups in the 2- and 3-positions of the anhydroglucose unit are substituted with methyl groups and wherein s26 is the molar fraction of anhydroglucose units wherein only the two hydroxy groups in the 2- and 6-positions of the anhydroglucose unit are substituted with methyl groups. | 2016-04-28 |
20160114048 | THERMOLABILE DRUG RELEASE FORMULATION - The present invention relates to a drug release formulation, in particular a sustained release formulation for ophthalmic applications and a method of preparing same. The method is based on the hydration of a given solid polymeric matrix material under mild conditions, allowing versatility with respect to the drug to be formulated. Both said solid polymeric matrix material as well the API hydrated formulation is an object of the present invention. The thus obtained material is particularly suitable for prolonged and sustained delivery of medication to the eye. Thus in a further aspect, the present invention provides the use of said solid polymeric matrix material as well the API hydrated formulation, in ophthalmic applications. | 2016-04-28 |
20160114049 | RNAi VITAMIN D CONJUGATES - The invention provides non-hormonal vitamin D conjugated to therapeutic RNA compounds that result in the compounds having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the therapeutic RNA compounds via the third carbon on the vitamin D backbone. | 2016-04-28 |
20160114050 | Heparosan/Therapeutic Prodrug Complexes and Methods of Making and Using Same - Compositions, methods, and systems are disclosed for the development and use of heparosan, a natural polymer related to heparin, as a new therapeutic modifying agent or complexation vehicle which can modulate drug cargo pharmacokinetics and behavior within a mammalian patient. In certain non-limiting embodiments, the use of heparosan is complexed with anti-cancer drugs and the like, thus forming a prodrug for the purposes of increasing efficacy and reducing side effects compared to the parental drug alone. | 2016-04-28 |
20160114051 | BORDETELLA PERTUSSIS LOS-DERIVED OLIGOSACCHARIDE WITH PERTUSSIS TOXIN GLYCOCONJUGATE AND ITS APPLICATION IN THE PROPHYLAXIS AND TREATMENT OF INFECTIONS CAUSED BY BORDETELLA PERTUSSIS - The present invention relates to an immunogenic and a non-toxic glycoconjugate comprising | 2016-04-28 |
20160114052 | POTENT CONJUGATES AND HYDROPHILIC LINKERS - Linkers for binding drugs to cell binding agents are modified to hydrophilic linkers by incorporating a polyethylene glycol spacer. The potency or the efficacy of the cell-binding agent-drug conjugates is surprisingly enhanced several folds in a variety of cancer cell types, including those expressing a low number of antigens on the cell surface or cancer cells that are resistant to treatment. A method for preparing maytansinoids bearing a thioether moiety and a reactive group which allows the maytansinoid to be linked to a cell-binding agent in essentially a single step is also provided. | 2016-04-28 |
20160114053 | METHODS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS WITH ENHANCED PHARMACOLOGICAL PROPERTIES - Provided herein are methods of enhancing in vivo efficacy of an active agent, comprising: administering to a subject an active agent that is coupled to a bioelastic polymer or elastin-like peptide, wherein the in vivo efficacy of the active agent is enhanced as compared to the same active agent when administered to the subject not coupled to (or not associated with) a bioelastic polymer or ELP. | 2016-04-28 |
20160114054 | CONJUGATES FOR PROTECTION FROM NEPHROTOXIC ACTIVE SUBSTANCES - The present invention relates to a conjugate containing at least one kidney-selective carrier molecule and at least one active compound which has a protective action for the kidney against nephrotoxic active compounds, to a process for the preparation of the conjugate, to the use thereof for the protection of the kidney against nephrotoxic active compounds, and to a medicament comprising the conjugate. | 2016-04-28 |
20160114055 | POLYMER DRUG CONJUGATES FOR THE TREATMENT OF AMYLOIDOSIS - The present invention is referred to novel polymeric conjugates to which at least it is linked a fibril disruptor agent and/or a aggregates blocking agent, and additionally a targeting moiety and/or a probe for therapy and diagnosis. | 2016-04-28 |
20160114056 | ENZYMATIC CONJUGATION OF POLYPEPTIDES - One embodiment relates to methods for the enzymatic functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions. | 2016-04-28 |
20160114057 | MODULAR PROTEIN DRUG CONJUGATE THERAPEUTIC - The invention provides modular antibody-therapeutic agent conjugates and antibody-detectable-agent conjugates, and methods of using said conjugates in therapeutic and diagnostic procedures. | 2016-04-28 |
20160114058 | POLYMER MICELLE PHARMACEUTICAL COMPOSITION - A polymer micelle pharmaceutical composition is provided and includes: a block copolymer unit α having a hydrophilic polymer chain segment and a hydrophobic polymer chain segment; and a block copolymer unit β having a hydrophilic polymer chain segment and a hydrophobic polymer chain segment, wherein: the block copolymer unit α and the block copolymer unit β are radially arranged in the state in which the hydrophilic polymer chain segments are directed outward and the hydrophobic polymer chain segments are directed inward; and the hydrophobic polymer chain segment of the block copolymer unit α is constituted of repeating units having side chains, at least one of the side chains having a hydrophilic group. | 2016-04-28 |
20160114059 | Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof - The present invention relates to methods and compositions for treating, ameliorating or preventing a disease or disorder in a subject by introducing into cells of the subject a therapeutic gene switch construct that controls expression of one or more therapeutic products. | 2016-04-28 |
20160114060 | PSMA-BINDING AGENTS AND USES THEREOF - Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis. | 2016-04-28 |
20160114061 | KIT FOR PREPARATION OF TARGET RADIOPHARMACEUTICALS AND METHOD OF USING IT - The invention relates to a kit for preparation of target radiopharmaceuticals, a method of using the kit to prepare target radiopharmaceuticals and use of the target radiopharmaceuticals. The target radiopharmaceuticals comprise a radio-nuclear loading on liposome and inhibit the tumor growth and metastatic progression of head and neck cancer, lung cancer and brain cancer. The radiopharmaceuticals may be used for treating the mentioned cancers. | 2016-04-28 |
20160114062 | TREATMENT OF IMMUNE, INFLAMMATORY AND DEGENERATIVE ARTHRITIDES WITH TIN-117m - Immune, inflammatory and degenerative arthritides, including rheumatoid arthritis, hemophiliac arthropathy and osteoarthritis, can be treated using a systemic or intra-articular radiosynovectomy technique in which the radionuclide is high specific activity tin-117m. Tin-117m can either be bound to a colloid typically used in an intra-articular radiosynovectomy (RSV), or can be tin-117m annexin for RSV and systemic administration. | 2016-04-28 |
20160114063 | PHARMACEUTICAL PREPARATION - The present invention provides a method for generating a purified solution of at least one alpha-emitting radionuclide complex. The method comprises contacting a solution of the alpha-emitting radionuclide complex and at least one daughter nuclide with at least one selective binder for the daughter nuclide and subsequently separating the solution from the selective binder. The invention also provides a method for the removal of at least one daughter radionuclide from a solution comprising at least one alpha-emitting radionuclide complex. The method comprises contacting the solution with at least one selective binder for the daughter nuclide. | 2016-04-28 |
20160114064 | METHOD FOR CLEANING DISSOLUTION VESSELS AND SUBSEQUENT DOSING OF A DISSOLUTION MEDIA, AND MOBILE MODULAR CLEANING AND DOSING EQUIPMENT FOR THE IMPLEMENTATION THEREOF - The invention relates to a method for cleaning dissolution vessels and for the subsequent dosing of a dissolution media, and to mobile modular cleaning and dosing equipment for the implementation of said method. According to said method, injected water steam is used for the cleaning and is subsequently aspirated, together with the residues of the dissolution, and the vessel is then refilled with the desired quantity of a new dissolution media. The mobile modular cleaning and dosing equipment allows the cleaning and dosing to be carried out in situ without having to remove the dissolution vessels from the equipment or site where the dissolution tests are carried out, using self-sufficient modular equipment, and a novel steam supply line is used for the cleaning, which sprays the steam against the bottom of the vessel and the inner side walls. | 2016-04-28 |
20160114065 | Method and System for Sterilizing an Analyte Sensor - In one aspect, there is provided assembling an analyte sensor with an analyte sensor insertion device, packaging the assembled analyte sensor and sensor insertion device in a substantially airtight seal, and irradiating the packaged assembled analyte sensor and sensor insertion device at a predetermined dose using one or more electron beam accelerators. | 2016-04-28 |
20160114066 | Ultraviolet High-Level Ultrasound Transducer Disinfection System - A UVC disinfection system which produces a dosage of UVC radiation sufficient to kill | 2016-04-28 |
20160114067 | Flexible Article for UV Disinfection - A device including a flexible substrate and an ultraviolet radiation system is disclosed. The ultraviolet radiation system can include at least one ultraviolet radiation source configured to emit ultraviolet radiation towards a surface to be disinfected, an ultraviolet transparent component configured to focus the ultraviolet radiation, and a control system configured to control the at least one ultraviolet radiation source. The device can include a hand article, such as a glove. | 2016-04-28 |
20160114068 | TWO-PHASE EXHAUSTION INDICATOR FOR FRAGRANCE RELEASE SYSTEMS - A two-phase system containing at least one solvatochromic dye, water, at least one fragrance, and at least one solvent. Wherein the two-phase system includes liquid phases layered one on top of the other. The inventive compositions can be used as exhaustion indicators for fragrance release systems. | 2016-04-28 |
20160114069 | AN APPARATUS AND METHOD FOR DIFFUSING A CHEMICAL SUBSTANCE - The present invention provides an apparatus for diffusing a chemical substance comprising: a chamber having a diffusing member arranged to diffuse a chemical substance to air disposed within the chamber, wherein the chamber is in communication with an air-inlet arranged to receive air from an exterior of the chamber and an air-outlet arranged to expel air from within the chamber. | 2016-04-28 |
20160114070 | REMOTELY DEPLOYABLE VAPOR DELIVERY DEVICE - A remotely deployable vapor delivery device is described that is conveniently and effectively deployed in a hard-to-reach location. The device is approximately spherical in shape, and includes an integrated reservoir containing the desired vapor producing substance, an evaporative surface and means for continuous flow of the vapor producing substance from the integrated reservoir to the evaporative surface which provides an approximately constant vapor delivery rate. The advantages of the embodiments include a device that can be conveniently tossed or rolled, is compact in size, provides a maximal amount of stored vapor producing substance, has an efficient usage rate of the stored vapor producing substance and provides a long operating lifetime. Other advantages of the embodiments described include hands-free activation, self-righting after deployment, tamper resistance, non-energized operation, a modest number of low cost parts that are readily manufactured and assembled, and easy retrieval. | 2016-04-28 |
20160114071 | Absorbent Article Containing a Porous Polyolefin Film - An absorbent article containing a polyolefin film is provided. The polyolefin film is formed by a thermoplastic composition containing a continuous phase that includes a polyolefin matrix polymer and nanoinclusion additive is provided. The nanoinclusion additive is dispersed within the continuous phase as discrete nano-scale phase domains. When drawn, the nano-scale phase domains are able to interact with the matrix in a unique manner to create a network of nanopores. | 2016-04-28 |
20160114072 | MEDICAL MATERIAL EMPLOYING CARBOXYMETHYL CELLULOSE - The purpose of the present invention is to provide a medical material which, while retaining high liquid absorbency and styptic properties through gelation of CMC, can maintain shape stability even after absorbing a liquid; which has excellent conformance to the skin; and through which the body surface to which it is to be applied is visible. This medical material is a structure comprising regenerated cellulose fibers including carboxymethyl cellulose fibers in which the degree of substitution of the hydroxyl groups in the glucose units making up the cellulose molecule is at least | 2016-04-28 |
20160114073 | Antioxidant Wound Dressing Materials - A wound dressing material comprising a solid bioabsorbable substrate dyed with an antioxidant dyestuff. The substrate may comprise collagen, chitosan or oxidized regenerated cellulose, and the dyestuff may for example be an aniline or acridine dye. The material preferably also comprises a silver salt, whereby the dyestuff stabilizes the silver salt. Also provided are methods of making such materials, and wound dressings comprising such materials. | 2016-04-28 |
20160114074 | ABSORBENT MATERIAL - This invention relates to absorbent materials useful in the manufacture of absorbent articles, in particular dressings for the advanced wound care market. The absorbent materials of the present invention are sulfonated polysaccharides, particularly water-insoluble cellulose alkyl sulfonates in which the cellulose is substituted by one type of alkyl sulfonate group. The invention also provides a process for the manufacture of such materials. The preferred cellulose alkyl sulfonate described herein is cellulose ethyl sulfonate. Reinforcing fibers and/or antimicrobial agents are optionally applied to the cellulose alkyl sulfonate. | 2016-04-28 |
20160114075 | PHOTOACTIVATED CROSSLINKING OF A PROTEIN OR PEPTIDE - A method of crosslinking a protein or peptide for use as a biomaterial, the method comprising the step of irradiating a photoactivatable metal-ligand complex and an electron acceptor in the presence of the protein or peptide, thereby initiating a cross-linking reaction to form a 3-dimensional matrix of the biomaterial. | 2016-04-28 |
20160114076 | IMPLANT WITH CONTROLLED POROSITY MADE OF A HYBRID MATERIAL - The disclosure relates to an implant material for filling bone defects, for bone regeneration, and for bone tissue engineering, to an implant comprising this material, to a method for producing such an implant, and to a method for producing a hybrid material. The implant material comprises a hybrid material comprising: a bioactive glass M based on SiO | 2016-04-28 |
20160114077 | ELASTOMERIC AND DEGRADABLE POLYMER SCAFFOLDS AND HIGH-MINERAL CONTENT POLYMER COMPOSITES, AND IN VIVO APPLICATIONS THEREOF - This invention provides novel synthetic bone grafting materials or tissue engineering scaffolds with desired structural and biological properties (e.g., well-controlled macroporosities, spatially defined biological microenvironment, good handling characteristics, self-anchoring capabilities and shape memory properties) and methods of their applications in vivo. | 2016-04-28 |
20160114078 | TREATMENT OF SKELETAL VOIDS WITH IMPLANTABLE SUBSTRATE HYDRATED WITH BONE MARROW CONCENTRATE - The invention is directed to a bone void filler comprising a scaffold or matrix. The scaffold or matrix may include a porous inorganic matrix component. The bone void filler may include a cellular component containing cells, some of which are capable of making extracellular matrix resembling native bone tissue. The bone void filler may include an organic matrix, such as, an organic biopolymer that aids in cell retention and renders the scaffold or matrix moldable. The bone void filler may include growth factors and/or cytokines. The bone void filler may include a clotting agent. | 2016-04-28 |
20160114079 | Composite Grafts, Systems, and Methods - Composite grafts including a biocompatible, synthetic scaffold; and a biological tissue component obtained or derived from a deceased donor tissue, wherein the biological tissue component is embedded in the biocompatible, synthetic scaffold, are provided as systems relating thereto. Methods of manufacture and methods of treatment using such grafts are also provided. | 2016-04-28 |
20160114080 | Elastase Treatment of Tissue Matrices - A method of producing a modified acellular tissue matrix (mATM) from an acellular tissue matrix (ATM), where the mATM has a reduced stretchiness relative to the ATM, without substantially compromising its associated structural or functional integrity. The method includes providing an acellular tissue matrix (ATM) and exposing the ATM to elastase for a period of time. | 2016-04-28 |
20160114081 | METHODS AND COMPOSITIONS FOR BLOOD VESSEL TISSUE REPAIR AND ENGINEERING - The present disclosure provides methods and compositions for modifying, repairing, and/or engineering blood vessel tissue, and in particular the use of such compositions for treating a diseased blood vessel. | 2016-04-28 |
20160114082 | ODOR BARRIER FILM - A multilayer film for ostomy and bowel management applications includes a barrier layer comprising at least about 90% wt. nylon 6/69. The multilayer film provides excellent mechanical and odor barrier properties, and softness and quietness desired in ostomy and bowel management applications. | 2016-04-28 |
20160114083 | DRUG DELIVERY SYSTEM AND METHOD OF MANUFACTURING THEREOF - In one embodiment, a drug delivery system and method provide a member including a combination of a drug substance and a polymer or other material, and an encapsulating layer formed in an outer surface of the member by gas cluster ion beam irradiation of the outer surface of the member, which encapsulating layer is adapted to determine one or more characteristics of the drug delivery system. | 2016-04-28 |
20160114084 | SUCTION DEVICE FOR SURGICAL INSTRUMENTS - A suction device is shown and described. The suction device includes a body, an input port configured to receive a flow of matter, a suction port, and a suction lumen that couples the suction port to the input port. In some embodiments the suction device is configured to couple with a surgical instrument for use in a surgical procedure. | 2016-04-28 |
20160114085 | SUCTION DEVICE FOR SURGICAL INSTRUMENTS - A suction device is shown and described. The suction device includes a body, an input port configured to receive a flow of matter, a suction port, and a suction lumen that couples the suction port to the input port. In some embodiments the suction device is configured to couple with a surgical instrument for use in a surgical procedure. | 2016-04-28 |
20160114086 | SUCTION DEVICE FOR SURGICAL INSTRUMENTS - A suction device is shown and described. The suction device includes a body, an input port configured to receive a flow of matter, a suction port, and a suction lumen that couples the suction port to the input port. In some embodiments the suction device is configured to couple with a surgical instrument for use in a surgical procedure. | 2016-04-28 |
20160114087 | SUCTION DEVICE FOR SURGICAL INSTRUMENTS - A suction device is shown and described. The suction device includes a body, an input port configured to receive a flow of matter, a suction port, and a suction lumen that couples the suction port to the input port. In some embodiments the suction device is configured to couple with a surgical instrument for use in a surgical procedure. | 2016-04-28 |
20160114088 | SUCTION DEVICE FOR SURGICAL INSTRUMENTS - A suction device is shown and described. The suction device includes a body, an input port configured to receive a flow of matter, a suction port, and a suction lumen that couples the suction port to the input port. In some embodiments the suction device is configured to couple with a surgical instrument for use in a surgical procedure. | 2016-04-28 |
20160114089 | MULTI-CONDUIT CONNECTORS AND METHODS FOR NEGATIVE PRESSURE WOUND THERAPY - Multi-conduit connector apparatuses for use in negative pressure wound therapy (NPWT) apparatuses to wound dressing, and methods for installing multi-conduit connector apparatuses in NPWT apparatuses. | 2016-04-28 |
20160114090 | BREAST PUMP ADAPTOR AND METHOD OF FILLING BAG - An adaptor, system, and method for collecting for a breast pump. A breast milk bag has a hole adjacent an end margin. The bag can have a reclosable seal and a zone of weakness for separating a sealed portion from a header. An adaptor has inlet end and an outlet end and defines a flow passage. The inlet end is securable to the outlet of the breast pump so liquid therefrom can flow through the flow passage. A slot extends through the adaptor wall to at least partially define a retainer for extending through the hole to mount the bag on the adapter. In a method of use, the bag is secured to the adaptor using the retainer, filled with breast milk, sealed while secured to the adaptor, and the sealed portion of the bag can be removed by tearing the bag along the zone of weakness. | 2016-04-28 |